Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Metoject PEN 15mg/0.3ml inj pre-filled pens
1001030U0BEAXCC
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 17,726 |
|
Ibuprofen 600mg tablets
1001010J0AAAFAF
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 16,291 |
|
Diethylamine salicylate 10% cream
1003020I0AAAAAA
|
Diethylamine salicylate | Diethylamine salicylate | Musculoskeletal and Joint Diseases | 15,190 |
|
Indometacin 50mg capsules
1001010K0AAABAB
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | 15,034 |
|
Diclofenac 100mg suppositories
1001010C0AAACAC
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 14,412 |
|
Methylprednisolone acetate 40mg/1ml inj vials
1001022K0AAAAAA
|
Methylprednisolone acetate | Methylprednisolone acetate | Musculoskeletal and Joint Diseases | 13,902 |
|
Capsaicin 0.075% cream
1003020AAAAAAAA
|
Capsaicin | Capsaicin | Musculoskeletal and Joint Diseases | 13,454 |
|
Depo-Medrone 80mg/2ml suspension for injection vials
1001022K0BBABAB
|
Depo-Medrone | Methylprednisolone acetate | Musculoskeletal and Joint Diseases | 13,288 |
|
Indometacin 25mg capsules
1001010K0AAAAAA
|
Indometacin (Systemic) | Indometacin | Musculoskeletal and Joint Diseases | 10,548 |
|
Tizanidine 4mg tablets
1002020T0AAAAAA
|
Tizanidine hydrochloride | Tizanidine hydrochloride | Musculoskeletal and Joint Diseases | 10,531 |
|
Salicylic acid 2% / Mucopolysaccharide polysulfate 0.2% gel
1003020W0AAAAAA
|
Heparinoid (Topical Antirheumatic) | Heparinoid | Musculoskeletal and Joint Diseases | 10,422 |
|
Triamcinolone acetonide 40mg/1ml inj vials
1001022U0AAABAB
|
Triamcinolone acetonide (Musculoskeletal) | Triamcinolone acetonide | Musculoskeletal and Joint Diseases | 10,307 |
|
Febuxostat 120mg tablets
1001040V0AAABAB
|
Febuxostat | Febuxostat | Musculoskeletal and Joint Diseases | 9,467 |
|
Dantrolene 25mg capsules
1002020J0AAAAAA
|
Dantrolene sodium (Systemic) | Dantrolene sodium | Musculoskeletal and Joint Diseases | 9,065 |
|
Movelat cream
1003020W0BBAAAB
|
Movelat | Heparinoid | Musculoskeletal and Joint Diseases | 8,885 |
|
Methylprednisolone 40mg / Lidocaine 10mg/1ml (1%) inj vials
1001022K0AAAGAG
|
Methylprednisolone acetate | Methylprednisolone acetate | Musculoskeletal and Joint Diseases | 8,730 |
|
Ibuprofen 800mg modified-release tablets
1001010J0AAAPAP
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | 8,495 |
|
Naproxen 500mg / Esomeprazole 20mg modified-release tablets
1001010P0AABBBB
|
Naproxen | Naproxen | Musculoskeletal and Joint Diseases | 7,550 |
|
Diclofenac sodium 75mg modified-release capsules
1001010C0AAAWAW
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 7,539 |
|
Metoject PEN 10mg/0.2ml inj pre-filled pens
1001030U0BEAZCE
|
Metoject (Rheumatism) | Methotrexate | Musculoskeletal and Joint Diseases | 7,524 |
|
Diclofenac 50mg suppositories
1001010C0AAAUAU
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 7,415 |
|
Diclofenac sodium 75mg modified-release tablets
1001010C0AAALAL
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 7,172 |
|
Etoricoxib 120mg tablets
1001010AJAAACAC
|
Etoricoxib | Etoricoxib | Musculoskeletal and Joint Diseases | 6,697 |
|
Diclofenac sodium 1% gel
1003020U0AAAKAK
|
Diclofenac sodium (Topical) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 6,640 |
|
Ibugel Forte 10% gel
1003020P0BDABAI
|
Ibugel | Ibuprofen | Musculoskeletal and Joint Diseases | 6,273 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.